ArticleCombinatorial chemistry & high throughput screening2026
Overexpression of ANAPC1 Affects the Cell Cycle Pathway to Promote the Progression of Lung Adenocarcinoma.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnaphase-Promoting Complex Subunit 1 (ANAPC1) plays a critical regulatory role in cell mitosis and is also an important contributor to tumorigenesis. However, its specific function in Lung Adenocarcinoma (LUAD) has not yet been systematically investigated.
aimsThis research aims to evaluate the expression and clinicopathological significance of ANAPC1 in LUAD, and to explore its molecular mechanisms and biological functions.
methodsA total of 4,813 samples from multiple databases were integrated to assess ANAPC1 mRNA expression. Additionally, 122 clinical samples were collected to detect ANAPC1 protein expression via immunohistochemistry. The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) screening assessed the ANAPC1 knockout effect in LUAD cell lines. Enrichment and immune-related analyses were conducted to explore the molecular basis of ANAPC1 in LUAD. The prognostic value of ANAPC1 was assessed using Kaplan-Meier curves and Cox regression models. Finally, immunoassay, drug concentration, and molecular docking for ANAPC1 were calculated.
resultsANAPC1 mRNA was significantly upregulated in LUAD (SMD = 0.74, 95% CI [0.41; 1.07]; AUC = 0.82 [0.79-0.85]), and overexpression was confirmed at the protein level (p < 0.0001, AUC: 0.999 [0.996-1.000]). CRISPR screening showed that ANAPC1 knockout in 19 LUAD cell lines inhibited cell growth. Most high-expression co-expressed genes associated with ANAPC1 were primarily enriched in cell cycle and mitosis pathways. ANAPC1 expression correlated with immune cell infiltrations and was identified as a prognostic risk factor in LUAD (HR = 1.42, 95% CI: 1.02-1.98). Patients with high ANAPC1 expression exhibited lower immune phenotype scores and higher tumor immune dysfunction and exclusion scores. Higher ANAPC1 expression showed lower predicted drug concentrations (docetaxel, paclitaxel, gefitinib, and crizotinib).
conclusionsUpregulated ANAPC1 expression in LUAD patients indicates potential predictive value for poor prognosis. Overexpression of ANAPC1 may contribute to LUAD progression by promoting cell growth and altering the cell cycle.
Indexed as
Identifiers
42002993What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.